China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. The Group was established in 1995, and was listed on the Main Board Market of the Stock Exchange of Hong Kong Limited (stock code: 867) on 28 September 2010. CMS has been included in the Morgan Stanley Capital International (MSCI) China Index as well as the Hang Seng Stock Connect Biotech 50 Index (HSSCB50), and is the object of transaction in both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect. The Group is also the largest shareholder of Tibet Rhodiola Pharmaceutical Holding Co. (stock code: 600211), a listed company of Shanghai Stock Exchange (A-share).

By capitalizing on its resources of global product development for more than two decades, as well as its market reputation, CMS has established the strategic cooperation with a number of leading pharmaceutical companies around the world and made equity investments in R&D companies from the UK, France, the US and Switzerland. The Group’s innovative pipeline includes the products with great market potential and competitive differentiation advantages at relatively high innovation level and with a wide range of therapeutic areas. CMS has become a trustworthy and highly recognized cooperation partner for world’s leading pharmaceutical and innovative R&D companies who are willing to enter China market.

With the benefits of its proven and successful experiences in drug commercialization for over two decades, the Group has created good sales records for a number of quality branded drugs and received the high recognition from dozens of world’s leading pharmaceutical companies. The Group concentrates on exploring the evidence-based medical evidence and differentiation competitive advantages of the drugs, and has established a professional, compliant and efficient academic promotion system. Combined with its timely, refined, transparent and efficient internal management system, the Group has become one of the most efficient pharmaceutical companies in the field of marketing and promotion of prescription drugs.

Along with the value chain of pharmaceutical industry, CMS has paid special attention to two core elements, product competence and promotion capability. Over the past decade (from 2010 to 2019), the Group has achieved the rapid growth with a turnover compound annual growth rate (“CAGR”) of 25.6%, and a net profit CAGR of 28.4%. The Group’s return on equity has maintained over 20% for more than a decade. By converging the R&D forces and innovative resources around the world, CMS will work diligently to fulfill its mission to continually introduce more affordable innovative products with differentiation competitive advantages to benefit more Chinese patients and their families.